Becton, Dickinson and Company (BDX) Receives FDA Clearance for New Breast Biopsy System, Expected Market Launch in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy BDX?
Source: Benzinga
- FDA Approval: The U.S. FDA granted clearance for Becton, Dickinson and Company's EnCor EnCompass Breast Biopsy and Tissue Removal System, expected to launch in early 2026, enhancing the biopsy experience across various imaging modalities and strengthening market competitiveness.
- Stable Market Valuation: BDX maintains a market capitalization of $59.10 billion, with a 52-week stock range of $162.29 to $251.99, reflecting robust performance in the medical device sector and aligning with broader market trends, indicating investor confidence in future growth.
- Positive Technical Indicators: BDX's Relative Strength Index (RSI) stands at 66.21, indicating neutral to bullish momentum, while a MACD of 2.94 suggests strong price momentum, potentially providing a favorable entry point for investors.
- Earnings Forecast: Analysts project earnings per share of $2.82, down from $3.43 last year, with revenue slightly decreasing to $5.15 billion; however, the consensus Buy rating and an average price target of $245.93 reflect optimism about the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 206.510
Low
183.00
Averages
202.38
High
220.00
Current: 206.510
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Release Announcement: Becton Dickinson is set to release its Q1 earnings before the market opens on February 9, with analysts projecting earnings of $2.81 per share, down from $3.43 last year, indicating a potential decline in profitability that may affect investor confidence.
- Revenue Expectations Decline: The company anticipates quarterly revenue of $5.15 billion, slightly lower than last year's $5.17 billion, reflecting soft market demand that could pressure stock prices and influence future investment decisions.
- Share Buyback Plan: Announced on January 27, Becton Dickinson's plan to repurchase up to 10 million shares aims to enhance earnings per share and shareholder returns, potentially attracting more investor interest in the company's long-term value.
- Dividend Yield Analysis: With an annual dividend yield of 2.03% and a quarterly dividend of $1.05, investors seeking $500 monthly dividends would need to invest approximately $295,103, highlighting the company's dividend policy's appeal to income-focused investors.
See More
- Aecom Earnings Forecast: Aecom (NYSE:ACM) is projected to report quarterly earnings of $1.17 per share on revenue of $3.61 billion, indicating stable growth in the infrastructure sector that may enhance investor confidence.
- Stock Performance: Aecom shares rose 2.4% to close at $101.03 on Friday, reflecting optimistic market sentiment ahead of its earnings report, which could attract more investor attention.
- ON Semiconductor Earnings Outlook: Analysts expect ON Semiconductor Corp. (NASDAQ:ON) to post quarterly earnings of 62 cents per share with revenue of $1.54 billion, suggesting ongoing demand and growth potential in the semiconductor market.
- Stock Movement: ON Semiconductor shares gained 0.1% in after-hours trading, closing at $65.23, indicating market anticipation for its earnings report, which may influence future investment decisions.
See More
- Market Sentiment Improvement: The CNN Money Fear & Greed Index rose to 45 on Friday, entering the 'Neutral' zone from a previous reading of 34.2, indicating a significant improvement in market sentiment that could boost investor confidence.
- Dow Jones Surge: The Dow Jones Industrial Average jumped over 1,200 points during Friday's session, closing at 50,115.67 and marking its first breach of the 50,000-point milestone, showcasing a strong market rebound that may attract more capital inflows.
- S&P 500 Strong Performance: The S&P 500 rose by 1.97% to close at 6,932.30, with sectors like industrials, energy, and information technology recording significant gains, reflecting positive signals of economic recovery that could drive corporate earnings growth.
- Consumer Confidence Boost: The University of Michigan's consumer sentiment index increased by 0.9 points to 57.3 in February, surpassing market estimates of 55, indicating enhanced consumer confidence in the economic outlook, which may stimulate consumer spending and economic growth.
See More

- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
- Earnings Announcement Date: Becton, Dickinson (BDX) is set to announce its Q1 2023 earnings on February 9 before market open, with consensus EPS estimate at $2.81, reflecting an 18.1% year-over-year decline, and revenue estimate at $5.15 billion, down 0.4% year-over-year, indicating profitability challenges ahead.
- Historical Performance Review: Over the past two years, BDX has consistently beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating a degree of financial stability despite current pressures.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 7 downward adjustments, reflecting market caution regarding the company's future performance.
- Dividend Declaration: Becton, Dickinson has declared a dividend of $1.05 per share, maintaining its commitment to shareholders despite profitability pressures, which underscores the stability of its cash flow.
See More









